JP2016530259A5 - - Google Patents

Download PDF

Info

Publication number
JP2016530259A5
JP2016530259A5 JP2016533909A JP2016533909A JP2016530259A5 JP 2016530259 A5 JP2016530259 A5 JP 2016530259A5 JP 2016533909 A JP2016533909 A JP 2016533909A JP 2016533909 A JP2016533909 A JP 2016533909A JP 2016530259 A5 JP2016530259 A5 JP 2016530259A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
compound
substituted
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016533909A
Other languages
English (en)
Japanese (ja)
Other versions
JP6495908B2 (ja
JP2016530259A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/067263 external-priority patent/WO2015022332A1/en
Publication of JP2016530259A publication Critical patent/JP2016530259A/ja
Publication of JP2016530259A5 publication Critical patent/JP2016530259A5/ja
Application granted granted Critical
Publication of JP6495908B2 publication Critical patent/JP6495908B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016533909A 2013-08-14 2014-08-12 ピリジノン Active JP6495908B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13180404.9 2013-08-14
EP13180404 2013-08-14
PCT/EP2014/067263 WO2015022332A1 (en) 2013-08-14 2014-08-12 Pyridinones

Publications (3)

Publication Number Publication Date
JP2016530259A JP2016530259A (ja) 2016-09-29
JP2016530259A5 true JP2016530259A5 (OSRAM) 2017-09-21
JP6495908B2 JP6495908B2 (ja) 2019-04-03

Family

ID=48951412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016533909A Active JP6495908B2 (ja) 2013-08-14 2014-08-12 ピリジノン

Country Status (4)

Country Link
US (2) US20150051208A1 (OSRAM)
EP (1) EP3033335B1 (OSRAM)
JP (1) JP6495908B2 (OSRAM)
WO (1) WO2015022332A1 (OSRAM)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
EP2935253B1 (en) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
WO2015002754A2 (en) 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
WO2015015318A2 (en) 2013-07-31 2015-02-05 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
RS63733B1 (sr) 2013-10-18 2022-12-30 Celgene Quanticel Research Inc Inhibitori bromodomena
NZ719465A (en) * 2013-11-26 2017-03-31 Gilead Sciences Inc Quinoline derivatives as bromodomain inhibitors
ES2809535T3 (es) * 2013-12-09 2021-03-04 UCB Biopharma SRL Derivados de imidazopiridina como moduladores de la actividad de TNF
GB201321737D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2016087942A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridines as bromodomain inhibitors
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
GB201503720D0 (en) * 2015-03-05 2015-04-22 Glaxosmithkline Ip No 2 Ltd Chemical compound
CA2979070A1 (en) 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
CN108350062B (zh) 2015-08-06 2022-10-14 达纳-法伯癌症研究所股份有限公司 靶向蛋白降解以减弱过继性t细胞疗法相关的不良炎症反应
WO2017024406A1 (en) 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
CN108290856A (zh) 2015-08-11 2018-07-17 尼奥迈德研究所 芳基-取代的二氢喹诺酮、它们的制备和它们作为药物的用途
AU2016305515A1 (en) 2015-08-12 2018-03-08 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
CA3007168A1 (en) * 2015-12-14 2017-06-22 Zenith Epigenetics Ltd. 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
WO2017172914A1 (en) 2016-03-30 2017-10-05 Wisconsin Alumni Research Foundation Methods and compositions for modulating frataxin expression
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
GB201614939D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate
GB201614940D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
WO2018106667A1 (en) 2016-12-05 2018-06-14 Microbiotix, Inc. Broad-spectrum inhibitors of filoviruses
CN110612294B (zh) 2017-01-31 2024-01-16 阿尔维纳斯运营股份有限公司 人小脑蛋白配体和包含其的双官能化合物
WO2018148440A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
WO2018183679A1 (en) 2017-03-29 2018-10-04 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN109111437B (zh) * 2017-06-22 2022-03-04 中国科学院广州生物医药与健康研究院 一种苯并[d]异恶唑类化合物及其制备方法和应用
CN109280046B (zh) * 2017-07-21 2021-02-02 浙江海正药业股份有限公司 苯并咪唑类衍生物及其制备方法及其在医药上的用途
US11447466B2 (en) * 2017-08-04 2022-09-20 Bristol-Myers Squibb Company Substituted indole compounds useful as inhibitors of TLR7/8/9
WO2019145410A1 (en) * 2018-01-25 2019-08-01 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
US10442799B1 (en) 2018-04-07 2019-10-15 Fuqiang Ruan Heterocyclic compounds and uses thereof
MX2020010571A (es) 2018-04-13 2021-01-08 Arvinas Operations Inc Ligandos de cereblon y compuestos bifuncionales que los comprenden.
CN120698985A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
JP2022053557A (ja) * 2019-02-08 2022-04-06 マルホ株式会社 ピリドン誘導体
EP4424379A3 (en) * 2019-04-24 2024-10-30 Convergene Llc Small molecule bromodomain inhibitors and uses thereof
CA3152923A1 (en) 2019-09-30 2021-04-08 Keisuke Yamamoto Bet degrader
CN115175901B (zh) 2019-12-19 2024-03-22 阿尔维纳斯运营股份有限公司 用于雄激素受体的靶向降解的化合物和方法
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
WO2024050016A1 (en) 2022-08-31 2024-03-07 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004010207A1 (de) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
ZA200807715B (en) * 2006-03-09 2009-11-25 Pharmacopeia Inc 9-Heteroarylpurine MNK2 inhibitors for treating metabolic disorders
WO2008043019A1 (en) * 2006-10-04 2008-04-10 Pharmacopeia, Inc 8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression
CN102448458B (zh) * 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
EP2439197A1 (en) * 2010-10-07 2012-04-11 Santhera Pharmaceuticals (Schweiz) AG Substituted benzimidazole derivatives as melanocortin 4 receptor antagonists

Similar Documents

Publication Publication Date Title
JP2016530259A5 (OSRAM)
JP2016515561A5 (OSRAM)
JP2016540742A5 (OSRAM)
JP2017517565A5 (OSRAM)
JP2019524883A5 (OSRAM)
JP2014521688A5 (OSRAM)
JP2014511892A5 (OSRAM)
JP2015501833A5 (OSRAM)
JP2012532136A5 (OSRAM)
JP2014511891A5 (OSRAM)
JP2015504081A5 (OSRAM)
JP2016515560A5 (OSRAM)
JP2019517487A5 (OSRAM)
JP2013537203A5 (OSRAM)
JP2018524390A5 (OSRAM)
JP2015078230A5 (OSRAM)
JP2019526596A5 (OSRAM)
JP2015537020A5 (OSRAM)
JP2015509535A5 (OSRAM)
JP2018537413A5 (ja) 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物
JP2017537066A5 (OSRAM)
JP2013508279A5 (OSRAM)
JP2015516427A5 (OSRAM)
JP2019500387A5 (OSRAM)
JP2016503797A5 (OSRAM)